Technology ID
TAB-2621
Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine
E-Numbers
E-158-2013-2
E-158-2013-3
Lead Inventor
Semenova, Vera (CDC)
Co-Inventors
Quinn, Conrad (CDC)
Pohl, Jan (CDC)
Svoboda, Pavel (CDC)
Dalton, Shannon (CDC)
Schiffer, Jarad (CDC)
Soroka, Stephen (CDC)
Applications
Vaccines
Therapeutic Areas
Infectious Disease
Development Status
- Pre-clinical
- In vitro data available
Lead IC
CDC
ICs
CDC
Bacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection is achieved. Specifically, this invention relates to a screening method for determining protection against B. anthracis infection that involves testing a biological sample for the presence of antibodies to one or more predefined regions of B. anthracis PA. This technology may be important to any bioterrorism defense strategy.
Commercial Applications
- Novel anthrax vaccines
- Post-vaccination screening to determine if anthrax protection is achieved
- Biodefense
Competitive Advantages
- May require fewer vaccination follow-ups, while present anthrax vaccines require numerous rounds of injections and boosters for full-effectiveness.
- Identified peptide sequences, representing regions of PA, elicit an immune response in primate and human sera studies.
Licensing Contact: